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Abstract: Liver diseases represent a major global health issue, and currently, liver transplantation 
is the only viable alternative to reduce mortality rates in patients with end-stage liver diseases. 
However, scarcity of donor organs and risk of recidivism requiring a re-transplantation remain 
major obstacles. Hence, much hope has turned towards cell-based therapy. Hepatocyte-like cells 
obtained from embryonic stem cells or adult stem cells bearing multipotent or pluripotent 
characteristics, as well as cell-based systems, such as organoids, bio-artificial liver devices, 
bioscaffolds and organ printing are indeed promising. New approaches based on extracellular 
vesicles are also being investigated as cell substitutes. Extracellular vesicles, through the transfer of 
bioactive molecules, can modulate liver regeneration and restore hepatic function. This review 
provides an update on the current state-of-art cell-based and cell-free strategies as alternatives to 
liver transplantation for patients with end-stage liver diseases. 
Keywords: liver diseases; transplantation; cell therapy; extracellular vesicles; organoids; scaffolds; 
organ printing 
 
1. Introduction 
Cirrhosis and hepatocellular carcinoma cause approximately 2 million deaths per year, placing 
liver disorders among the top 20 most common causes of death worldwide [1]. Chronic exposure to 
excessive and prolonged use of alcohol, viral infections, metabolic disorders, toxins, non-alcoholic 
fatty liver and cancer are among the common causes of liver cirrhosis [2]. Advanced cirrhosis is 
generally considered irreversible, unlike its preceding steps (hepatitis and fibrosis), even when the 
causal agent is removed [3]. Currently, liver transplantation (LT) is the only viable alternative to 
reduce cirrhosis-induced mortality rates [4]. Given the importance of LT, much progress has been 
made regarding surgical and conservation techniques. Surgical improvements have mainly focused 
on the phases of reconstruction and anastomoses. For instance, Carmody et al. recently compared 
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biliary transposition to recipient biliary ductoplasty for biliary reconstruction, and showed that both 
techniques were useful in the case of significant bile duct size mismatch [5]. Regarding liver 
conservation, ex vivo normothermic machine perfusion of the organ safely and efficiently extends its 
conservation time until transplanted, hence allowing transport for longer distances. The 
physiological conditions of the organ (temperature, nutrients and oxygen) can thus be maintained 
outside the body and the risk of ischemic reperfusion injury prevented [6,7]. Moreover, Patrono et al. 
recently reported that hypothermic oxygenated machine perfusion reduced ischemia-reperfusion 
injury in liver grafts from brain-dead donors [8]. 
Scarcity of donor organs is the main limitation for LT. Thus, other surgical approaches have 
been studied, such as the use of “marginal” organs, and partial LT from living donors [9,10]. The 
marginal organs are obtained from donors even over the age of 60, and with hypernatremia and 
steatosis greater than 40% or with positive serology for hepatitis C (HCV) or B (HBV) virus as well 
[11]. However, with this strategy, there are limits related to post-transplantation survival which, to 
be bypassed, require a careful selection of donors. The partial transplantation, on the other hand, 
adopts the split technique, through which a liver is divided and transplanted to two patients (two 
adults or an adult and a child weighing less than 10 kg), hence permitting living-donor LT to be 
performed [10]. However, complications such as small for size syndrome or those of the biliary and 
vascular pathways, especially in recipients with high Model for End-Stage Liver Disease (MELD) 
scores, may ensue. Despite the fact that, in case of liver diseases caused by viral infections, new 
antiviral treatments have permitted significant advances, the risk of recidivisms that require a 
re-transplantation for other severe liver diseases remains a major obstacle [12–14]. Moreover, 
inflammatory responses and acute or chronic immune-mediated organ rejection, life-long 
requirement of immunosuppressive drugs, and incidence of postoperative infections following LT 
are still unresolved issues. Another hassle regards the finding of post-transplantation fibrosis upon 
evaluation of liver biopsies for histological changes in the long term [15]. Analysis of liver biopsies 
after 12 months or more post-LT in pediatric patients receiving liver allografts has revealed 
different degrees of inflammation and fibrosis, despite revealing normal liver function parameters 
[15,16]. Sinusoidal fibrosis and pericellular fibrosis are also commonly encountered in liver biopsy 
specimens following LT [17]. 
A possible alternative for LT may be xenotransplantation. To date, the only xenotransplant 
from pig donor to human has been performed in a 26-year-old patient with fulminant hepatitis, 
hepatic encephalopathy (HE) and coagulopathy [18]. Xenotransplantation led to an improvement in 
bile production, lactate clearance and stabilization of prothrombin times, decreased serum bilirubin 
levels, and transaminases. However, no neurological improvement was observed and the patient 
died 34 hrs after the xenotransplantation [18]. Other studies have been performed in non-human 
primates with genetically-engineered porcine livers and the recipient′s survival almost reached one 
month [19]. Thus, this strategy may be considered as a bridge therapy prior to LT in patients for 
whom no alternative is available. A potential limitation to this approach could be the transmission of 
porcine endogenous retroviruses. In the near future, following completion of more advanced 
preclinical studies, it will be possible to consider undertaking clinical trials [20–22]. 
It is to be noted that ethical concerns arise with liver transplantation, such as employing 
deceased donor organs, transplantation of HCV-infected donor livers into uninfected patients and 
their subsequent treatment with a direct-acting antiviral regimen, allocation of organs, and living 
donor transplantation [23,24]. Thus, alternative strategies are urgently required to overcome these 
problems related to LT. New resolute and lasting interventions need to be implemented to restore 
correct liver function. In recent years, cell-based and cell-free strategies as well as evolving 
technologies have shown promises as therapeutic alternatives in patients with end-stage liver 
diseases, when the liver′s regenerative capacity is impaired and endogenous liver stem cells can no 
longer cope with chronic insults. To this end, the present review aims at summarizing the current 
state of cell-based and cell-free alternatives to LT for patients with severe liver diseases. 
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2. Cell Therapy 
2.1. Hepatocyte Transplantation 
Hepatocytes, obtained from donor organs, can be transplanted without complex surgery into 
recipients for restoring hepatic function. These cells are isolated, using standardised perfusion 
techniques with collagenase, from human livers that are unsuitable for transplantation or from liver 
segments available after split transplantation [25]. Fresh hepatocytes can be delivered through 
intraportal, intrasplenic or intraperitoneal routes, or cryopreserved for use on demand. Usually 
5–10% of the total hepatic mass must be substituted to obtain therapeutic benefits, and multiple 
infusions are often necessary. 
The first hepatocyte transplantion in humans dates back to 1992 for the treatment of cirrhotic 
patients. However, the results of this first autologous transplantation were uncertain [26]. Since then, 
hepatocyte transplantation has been extended to other liver pathologies, including those induced by 
metabolic defects, such as urea cycle disorder and Crigler–Najjar syndrome. For instance, Fox et al. 
transplanted allogeneic hepatocytes into the liver of a 10-year old patient with Crigler–Najjar 
Syndrome type I, and observed clinically relevant long-term (up to 11 months) functioning of 
transplanted human hepatocytes conferring partial metabolic recovery [27]. The first European 
hepatocyte transplantation in adults was performed in a glycogen storage disease type 1a patient, 
and resulted in partial correction of metabolic abnormalities that lasted beyond 9 months [28]. 
Several transplantation schemes have been adopted with promising results (Table 1). Hepatocyte 
transplantation has also been performed in a case of fulminant hepatic failure induced by mushroom 
intoxication. A patient in hepatic coma following the ingestion of Amanita phalloides, and with very 
high values of International Normalized Ratio (INR) and Factor V, was infused with vital primary 
hepatocytes and with steroids and cyclosporine A as immunosuppressant over 30 h. Improvement 
in hepatic function ensued, and interestingly, signs of recurrence were absent, rendering it possible 
to suspend immunosuppression [29]. 
Importantly, hepatocyte transplantation can be used as bridging therapy awaiting organ 
transplantation (bridge to transplant) or for liver regeneration (bridge to recovery). Despite its 
advantages such as the lower invasiveness, repeatability, possibility of leaving the endogenous 
organ to promote self-regeneration, and individual autologous approach, hepatocyte 
transplantation still faces unmet challenges such as recovering enough viable cells from 
non-transplantable organs, in vitro culture and expansion without reduction in functionality, and 
cryopreservation without viability loss. Furthermore, post-transplantation problems include low 
engraftment of hepatocytes, and the need for immunosuppressive therapy due to the high 
antigenicity of hepatocytes [25]. Attempts to improve hepatocyte engraftment and repopulation in 
the recipient′s liver, thus giving a selective advantage to transplanted cells, for instance through 
partial hepatectomy, portal embolization or irradiation of the liver, are currently ongoing, and have 
been extensively reviewed in [30]. Moreover, the choice of donor organ for hepatocyte isolation is 
crucial. Importantly, the results of hepatocyte transplantation in 5 adult patients with acute liver 
failure and 4 pediatric ones with inborn metabolic disorders showed that this procedure is safe and 
feasible, as long as viable and metabolically functional human hepatocytes are employed [31,32]. 
Livers with more than 40% steatosis or from the elderly have lower hepatocyte yield, viability and 
survival after cryopreservation, and are therefore not recommended for hepatocyte isolation for 
transplantation [33]. 
Table 1. Some examples of primary hepatocyte transplantation schemes in the clinical setting. 
Disease Donor Type Conservation Type 
//Isolation method 
Number of cells 
//Injection route 
Outcome Reference 
Urea Cycle disorders 9-day old 
neonate (post 
mortem) 
Cryopreserved 
//3-step collagenase 
perfusion technique 
5.6 × 109  
//Intraportal 
Metabolic 
stabilisation from 
4 to 13 months 
Meyburg 
et al.[34] 
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Crigler-Najjar Syndrome 
Type I 
5-year old boy 
(post mortem) 
Stored at 4 °C in 
University of 
Wisconsin solution 
//3-step collagenase 
perfusion 
7.5 × 109  
//Intraportal 
Partial metabolic 
recovery up to 11 
months 
Fox et 
al.[27]  
Inherited Factor-VII 
Deficiency 
Unused donor 
livers 
Fresh and 
cryopreserved 
//Collagenase 
perfusion technique 
1.09 × 109 
2.18 × 109  
//Inferior mesenteric 
vein 
Improvement in 
coagulation 
defects; reduced 
demand for 
recombinant 
exogenous factor 
VII by 20% 
Dhawan et 
al.[35]  
Glycogen storage 
disease type Ia 
Unused 
cadaveric 
donors 
Fresh 
//2-step collagenase 
perfusion technique 
2 × 109 
//Intraportal 
Partial correction 
of metabolic 
abnormalities 
(increase in 
blood-glucose and 
larger and more 
persistent 
inhibition of 
lactate production 
compared to 
before 
transplantation). 
Muraca et 
al.[28] 
Glycogen storage 
disease type Ib 
Unused 
cadaveric 
donors 
Cryopreserved 
//2-step collagenase 
perfusion technique 
1st infusion: 1 × 109 
2nd infusion: 3 × 109  
//Intraportal 
Disappearing of 
hypoglycemic 
symptoms; 
body growth 
Lee et al. 
[36] 
Peroxisomal biogenesis 
disease 
Unused left 
liver segments 
of two 
compatible 
donors 
Fresh and 
cryopreserved 
//2-step collagenase 
perfusion technique 
2 × 109 
//spleno-mesenteric 
Improved general 
condition and 
weight gain; 
ability to walk 
autonomously 6 
months after 
transplantation 
Sokal et 
al.[37] 
Acute liver failure by 
mushroom intoxication 
Cadaveric 
donors 
Cryopreserved  
//Multicatheter 
collagenase 
perfusion technique 
5 × 109 
//4 out of 5 patients: 
intrasplenic 
2 out of 5 patients: 
intraportal 
3 out of 5 patients 
survived from 12 
to 52 days with 
improvement in 
clearance function. 
Bilir et 
al.[29]   
Argininosuccinate lyase 
deficiency 
Cadaveric 
donors  
Fresh and 
cryopreserved 
//2-step collagenase 
perfusion technique 
1st infusion: 7 
infusions over 1 
month: 1.7 × 1012  
2nd infusion: 0.3 × 
1012 and 0.7 × 1012  
the day after 
3rd infusion: 1 × 1012 
//Intraportal 
sequential infusions; 
portal percutaneous 
puncture 
3.5-year-old 
patient with 
sustained 
metabolic control 
and clinical 
evolution of 
disease from 
severe to moderate 
form  
Stéphenne 
et al.[38] 
2.2. Stem Cell Therapy 
The limitations of hepatocyte transplantation have encouraged the search for other alternatives 
to LT. Stem cells have become the most promising candidates for liver cell replacement due to their 
expandability and differentiation potential. Stem cells derived from embryonic or adult tissues can 
be induced to differentiate into Hepatocyte-Like Cells (HLCs) under specific culture conditions 
(Figure 1) and show promises for the treatment of severe liver diseases. Adult Stem Cells (AdSCs) 
offer the possibility of autologous transplantation and of overcoming ethical constraints compared 
to Embryonic Stem Cells (ESCs), and include Mesenchymal Stem/Stromal Cells (MSCs), 
hematopoietic stem cells (HSCs), Endothelial Progenitor Cells (EPCs), Liver Stem Cells (LSCs), 
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induced Pluripotent Stem Cells (iPSCs) and Spermatogonial Stem Cells (SSCs) (Figure 1). The use of 
these cells as well as other types of stem cells for liver therapy is discussed below. 
 
Figure 1. Sources of hepatic-like cells (HLCs) for stem cell therapy in liver disease. HLCs can be 
differentiated from embryonic stem cells (ESCs) derived from the inner cell mass of blastocysts, or 
from adult stem cells (AdSCs). The main types of AdSCs used for cell therapy are: mesenchymal 
stem/stromal cells (MSCs) isolated from blood, adipose tissue, cartilage, bone marrow and synovial 
membrane; hematopoietic stem cells (HSCs) found in the bone marrow and umbilical cord blood; 
biliary tree stem/progenitor cells (BTSCs) derived from the peribiliary glands of the adult and fetal 
human biliary tree or from the crypts of the gallbladder; endothelial progenitor cells (EPCs) taken 
from peripheral vessels and from bone marrow; liver stem cells (LSCs) localised in the liver. HLCs 
can be also obtained from induced pluripotent stem cells (iPSCs) obtained by reprogramming of 
adults cells by specific growth factors or spermatogonial stem cells (SSCs) derived from testis. 
2.2.1. HSCs and EPCs in Liver Repair 
HSCs originate in the embryonic liver, and successively migrate for definitive hematopoiesis to 
the bone marrow. They are highly plastic, showing differentiation into hematopoietic lineages as 
well as other non-hematopoietic lineages such as hepatic oval cells, hepatocytes, skeletal muscle 
cells, lung epithelial cells and cardiomyocytes [39]. Following liver damage, HSCs are mobilized in 
the peripheral circulation and are recruited to the site of injury [40]. HSCs may induce repair either 
through transdifferentiation into or fusion with hepatocytes or through the release of paracrine 
factors (Figure 2) [40]. Several clinical trials have been undertaken with HSCs for the treatment of 
liver cirrhosis; however, the outcome of the studies remains unclear [41]. 
Cells 2020, 9, 386 6 of 22 
 
 
Figure 2. The mechanism of action of stem cells in the treatment of liver diseases. Stem cell injection 
may act in several ways in supporting liver repair. Functional stem cells may substitute diseased 
liver cells and at the same time provide the wild-type gene in case of genetic deficiencies, hence 
serving as a platform for gene therapy. Stem cells also release soluble factors such as growth factors 
and cytokines/chemokines to dampen liver injury. Extracellular vesicles (EVs) harbouring 
biomolecules with restorative properties are also produced by stem cells and participate in liver 
regenerative process. 
2.2.2. MSCs in Liver Repair 
MSCs are considered one of the most effective multipotent cells capable of promoting 
transdifferentiation into hepatocytes, cell proliferation and neovascularization. MSCs, derived from 
different tissues, have been found to home to damaged liver and to contribute to its repair mainly 
through different mechanisms including their anti-inflammatory and immunomodulatory actions, 
(Figure 2) [42–44]. The mechanisms by which MSCs exert their therapeutic effects in models of liver 
cirrhosis are manifold as largely revealed from preclinical studies, and include activation of 
autophagy and downregulation of transforming growth factor (TGF)-β pathway [45], modulation of 
the key enzymes involved in glucose homeostasis [46], inhibition of activated stellate hepatic cells, 
decrease in collagen deposition, and increased remodelling of the extracellular matrix (ECM) [47]. 
However, MSCs scarcely engraft in the damaged area due to the inflammatory and toxic 
microenvironment. Strategies to improve MSC function and survival have been tested, and involve 
MSC priming approaches with inflammatory cytokines (for example, Tumor Necrosis Factor 
(TNF)α, Interferon (IFN)γ), hypoxic conditions, pharmacological drugs and chemical agents such as 
valproic acid, use of biomaterials (in spheroids) and different culture conditions (for example, 
addition of lipopolysaccharides) (extensively reviewed in [48]). 
Several clinical trials have been carried out using MSCs, for instance, in patients suffering from 
HBV-related cirrhosis, in whom the regulation of Treg/Th17 cells was observed [49], and in patients 
with alcoholic cirrhosis who showed a decrease in TGF-β1, COL1A1 and α-smooth muscle actin 
levels [50]. Suk et al., in patients with alcoholic cirrhosis, confirmed a reduction of hepatic collagen 
deposition and an increase in both liver function and MELD score after MSC transplantation [51]. 
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Improved liver function was also observed in two clinical trials involving, respectively, 26 and 60 
patients with autoimmune liver cirrhosis and hepatolenticular degeneration [52,53]. Further 
research is needed to define more precisely the therapeutic window and the optimal cell dosage 
required to further the benefits, as well as to clarify current controversies regarding MSC 
transplantation in the management of patients with liver fibrosis [54]. 
2.2.3. Liver Stem Cells 
LSCs represent another potential candidate for cell transplantation (Table 2). Using different 
approaches, several groups have isolated liver cells with stem cell properties from the human liver. 
The most studied for their liver regenerative capacities hitherto are the liver MSC-like cells. These 
cells express markers of mesenchymal cells such as vimentin and α-smooth muscle actin, as well as 
those of hepatocytes including albumin and several subtypes of cytochrome P450 [55,56]. Some cells 
also express pluripotency markers such as Oct4 and nanog [57]. Their propensity to engraft and 
restore liver function has been demonstrated in preclinical studies involving animal models of 
severe liver diseases [58]. For instance, we have recently demonstrated that human liver MSC-like 
cells (human LSCs or HLSCs) are capable of restoring UGT1A1 enzyme activity in an 
immunocompromised mouse model of Crigler–Najjar Syndrome type I (CNSI) and of improving the 
phenotype [59]. The safety of liver MSCs has also been evaluated in a Phase I/II clinical trial in 
patients affected by urea cycle disorder and Crigler–Najjar syndrome (Table 2) [60]. The results are 
very encouraging. The authors showed that a low incidence rate of adverse events and a very low 
rate of serious adverse events occurred 1 month after cell infusion [60]. Human liver MSCs could 
also partially reinstate metabolic activity in these patients. Equally encouraging results were 
reported very recently with human LSCs (HLSCs). LSCs were injected in pediatric patients with 
inherited neonatal-onset hyperammonemia for clinical safety evaluation (Table 2) [61]. Importantly, 
patients were not subjected to treatment with immunosuppressive agents, due to the low 
immunogenicity of the cells infused. Cell injection did not induce any adverse events or intra-and 
extra-hepatic complications. Steady levels of ammonia were found in these patients, despite an 
increase in protein intake by approximately 30%, showing the capacity of these human LSCs to 
offer a bridge therapy untill the newborns are ready to undergo LT [61]. 
Other types of stem cells in the human liver include the hepatobiliary progenitor cells, known 
as “oval” cells in mice. These cells were recently identified using single-cell RNA sequencing 
technology, and showed a distinct gene expression profile compared to other liver parenchymal 
populations [62]. The bipotentiality of these cells was shown upon differentiation into 
TROP-2/CK9-positive (biliary cells) or albumin/HNF4α-positive (hepatocytes). These cells also are of 
great interest for liver regeneration and further studies will witness their utility in human liver 
regeneration. 
Table 2. Clinical trials with LSCs (source: https://clinicaltrials.gov/ and 
https://www.clinicaltrialsregister.eu/). 
NCT 
Number/Eu
draCT 
-Number 
Title Recruitment Conditions 
//Intervention 
Age 
//Number of 
Participants 
Phases Start Date Outcomes/ 
Aims 
N
C
T0
17
65
24
3 
A Prospective, Open 
Label, Multicenter, 
Partially Randomized, 
Safety Study of One 
Cycle of Promethera 
HepaStem in Urea 
Cycle Disorders 
(UCD) and 
Crigler-Najjar 
Syndrome (CN) 
Paediatric Patients.  
Completed Urea Cycle 
Disorders, 
Crigler Najjar 
Syndrome 
//HepaStem 
infusion 
Up to 17 
Years 
//20 
participants 
Phase 
I/II 
March 
2012 
Long-term 
safety profile 
and 
preliminary 
efficacy of 
HepaStem in 
paediatric 
patients with 
Urea Cycle 
Disorders and 
Crigler-Najjar 
Syndrome 
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N
C
T0
36
32
14
8 In Vitro Evaluation of 
the Effect of HepaStem 
in the Coagulation 
Activity in Blood of 
Patients With Liver 
Disease 
Enrolling by 
invitation 
Decompensated 
Cirrhosis 
//Liver MSCs 
infusion 
12 Years to 
80 Years 
//15 
participants 
N/A December 
2017 
Blood 
parameters in 
patients with 
liver disease 
N
C
T0
38
84
95
9 
A Prospective, Open 
Label, Safety and 
Efficacy Study of 
Infusions of HepaStem 
in Urea Cycle 
Disorders Pediatric 
Patients 
Recruiting Urea Cycle 
Disorder 
//HepaStem 
infusion 
Up to 12 
Years 
//5 
participants 
Phase II July 2018 Safety and 
Efficacy Study 
of Infusion of 
HepaStem in 
Urea Cycle 
Disorders 
Pediatric 
Patients 
N
C
T0
29
46
55
4 
Multicenter Phase II 
Safety and Preliminary 
Efficacy Study of 2 
Dose Regimens of 
HepaStem in Patients 
With Acute on 
Chronic Liver Failure 
Recruiting Acute-on-Chron
ic-Liver Failure 
//HepaStem 
Infusion 
18 Years to 
70 Years 
//12 
participants 
Phase II December 
2016 
Safety and 
Efficacy of 2 
Dose Regimens 
of HepaStem in 
Patients With 
Acute on 
Chronic Liver 
Failure 
N
C
T0
39
63
92
1 
Multicenter, 
Open-label, Safety and 
Tolerability Study of 
Ascending Doses of 
HepaStem in Patients 
With Cirrhotic and 
Pre-cirrhotic 
Non-alcoholic 
Steatohepatitis 
Recruiting Nonalcoholic 
Steatohepatitis 
//HepaStem 
infusion 
18 Years to 
70 Years 
//24 
participants 
Phase 
I/II 
April 2019 Evaluation of 
incidence of 
Adverse Event 
N
C
T0
24
89
29
2 
Prospective, Open 
Label, Multicenter, 
Efficacy and Safety 
Study of Several 
Infusions of HepaStem 
in Urea Cycle 
Disorders Paediatric 
Patients 
Unknown Urea Cycle 
Disorders 
//HepaStem 
infusion 
Up to 12 
Years 
//20 
participants 
Phase II October 
2014 
Efficacy of 
HepaStem in 
Urea Cycle 
Disorders 
Paediatric 
Patients 
H
LS
C
 0
1–
11
, E
ud
ra
C
T-
N
o.
 
20
12
–0
02
12
0-
33
 
Human Liver Stem 
Cells (HLSCs) in 
patients suffering from 
liver-based inborn 
metabolic diseases 
causing 
life-threatening 
neonatal onset of 
hyperammonemic 
encephalopathy 
Completed Inherited 
Neonatal-Onset 
Hyperammone-
mia 
Up to 18 
years//3 
participants 
Phase I December 
2013 
Safety and 
evaluation of 
short- and 
long-term 
clinical and 
biochemical 
data after 
HLSCs 
injections 
2.2.4. Adult Pluripotent Stem Cells and Transdifferentiated Cells 
The pluripotent stem cells par excellence are the ESCs, which have paved the way to identifying 
and creating the next-generation of pluripotent stem cells. However, due to ethical constraints, 
human ESCs are not yet readily employed in the clinic. Research on hESCs is still ongoing. To this 
end, recently, clinical grade functional hepatocytes have been generated from human ESCs, and 
biosafety evaluation was performed in preclinical studies [63]. Whether these cells may be used in 
patients still needs to be addressed in terms of immunocompatibility and ethical limitations. 
IPSCs have great potential in the field of liver regeneration. IPSCs, derived from the 
reprogramming of adult cells, share ESC characteristics and have an unlimited capacity for 
differentiation but are not subject to ethical concerns. HLCs derived from iPSCs (iHLCs) using 
different approaches have shown hepatocyte functionality in vitro and in preclinical models as well 
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as potential for liver disease modelling and drug testing [64,65]. Several cell sources were employed 
in iHLCs generation, and the question regarding which source is the best for efficiently generating 
mature and transplantable hepatocytes capable of restoring liver function, still remains open. 
Recently, primary liver cells obtained through liver needle biopsy were also successfully 
reprogrammed into iPSCs and functional hepatocytes, but the latter had a distinct transcription 
profile with respect to the originating liver, suggesting that the tissue of origin does not impact 
much on the differentiation efficiency of iPSCs [66]. Despite the success in the generation of 
hepatocytes derived from iPSCs for transplantation, there is still a need to improve and solve the old 
challenges of engraftment and repopulation [67]. To date, no clinical trials with 
iPSC-derived-hepatocytes as a therapeutic alternative to LT have been carried out. 
Interestingly, somatic cells obtained from simple biopsies can undergo lineage reprogramming 
to generate functional human HLCs. While a direct lineage reprogramming was initially used to 
generate hepatocytes by transduction, for instance, with a cocktail of factors including HNF4α, this 
approach resulted in functional cells that had to be expanded through SV40 large T antigen 
introduction, for example [68,69]. Recently, a two-step conversion process was used by passing 
through the generation of expandable human hepatic progenitor cells, followed by the induction of 
hepatocyte maturation [70]. This approach can be used to obtain sufficient functionally-competent 
hepatocytes for transplantation in patients. 
Spermatogonial stem cells (SSCs) also show promise for liver regeneration. SSCs are derived 
from adult testes, and have the propensity to convert to pluripotent stem cells sharing features with 
ESCs in vitro. We and others have demonstrated that mouse SSCs can be efficiently induced to 
differentiate into functional HLCs in vitro, and that the transplanted HLCs engraft into mice livers 
[71–75]. The pluripotency characteristics of human SSCs are still being investigated. However, 
human SSCs also show high plasticity and were successfully used to generate functional HLCs in 
vitro. Chen et al. reported the direct transdifferentiation of human SSCs to bipotent hepatic stem 
cells expressing both hepatic and cholangiocyte markers, and then to mature and functional 
hepatocytes [76]. The potentiality of the SSCs for human liver regeneration requires further 
assessment in clinical studies. 
2.2.5. Current Limitations of Cell Therapy 
Despite the panoply of beneficial effects, there are still unmet challenges regarding cell-based 
therapy. For instance, the time taken to produce GMP (Good Manufacturing Practice)-grade cells for 
clinical use is too long, which is worsened by regulatory challenges and financial burden. 
Cytogenetic abnormalities may result from long-term cell culture and passages, and rigorous 
controls are required before use in patients. Cell counting and cell viability evaluation are 
fundamental aspects in these studies. Moreover, the percentage of cells engrafting in the liver is still 
very low and the underlying mechanisms responsible for their beneficial effects are not completely 
understood [77]. Achieving enough cell engraftment in histologically normal livers capable of 
conferring therapeutic benefits, such as in the case of CNSI, remains untackled. Loss of functional 
properties of injected cells may also occur over time. Different cell types require different delivery 
routes, and the cell source as well as dose and number of injections need to be optimised 
preclinically based on the liver disease etiology in order to avoid toxicity. In addition, the clinical use 
of ESCs and iPSCs, albeit their differentiation capacity into HLCs, are hampered by the risk of 
teratoma formation from possible residual cells with pluripotent properties. Another major concern 
regarding stem cell-based therapy regards the possibility of liver fibrosis and hepatocellular 
carcinoma development over time [78]. All these concerns have solicited the search for alternative 
and improved strategies. 
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2.3. Recent Improvements in Clinical Cell-Based Strategies 
2.3.1. Encapsulation 
To overcome some of the limitations of the use of cells as alternatives to LT, new methods have 
been devised. For instance, encapsulation of cells before transplantation provides controlled release 
of a wide range of drugs, cytokines, growth factors and hormones [22]. Cells are incorporated in 
polymerized, biocompatible and semi-permeable structures, called microspheres or microcapsules, 
which are composed of biologically active materials with adjustable permeability such as alginate 
[79]. The bidirectional diffusion of oxygen and metabolic products needed for cell survival and 
expansion, the control of the differentiation process towards a specific lineage, and the protection 
from host′s immune attack render this approach very attractive in the field of regenerative medicine 
[80]. 
Several cell types have been encapsulated for applications in different fields of tissue 
engineering, such as pancreas, myocardial, endoderm and bone tissue repair [81]. Human 
hepatocyte microbeads, generated in polymerized alginate, showed hepatocyte-specific function 
and lack of immunogenicity in vitro [82]. Moreover, transplantation of these microbeads 
intraperitoneally in rats provided metabolic support and rescued them from acute liver failure. 
Recently, iPSCs were differentiated in a 2D monolayer followed by 3D aggregation and further 
encapsulation in alginate capsules, resulting in enhanced hepatocyte phenotype or function 
compared to conventional culture conditions [83]. Furthermore, encapsulated human co-cultures 
were transplanted into immunocompetent mice without causing immune rejection for at least 24 
days, showing their clinical potential [83]. 
Several aspects of the microbead systems need improvement, such as their relatively low 
physical strength as well as the capsule instability due to ionic bonds between calcium ions and 
alginate. The physiological exchange of calcium ions with sodium ions also causes osmotic swelling 
and destabilization of the microcapsules. To overcome these problems, a new combination of 
sodium alginate with polyethylene glycol (PEG) has been developed; this confers greater mechanical 
strength and stability [79]. However, additional strategies that reduce potential fibrotic reactions and 
improve vascularisation should be considered as a further clue for the applicability of the 
encapsulation strategy in the clinical setting. 
2.3.2. Bioartificial Liver Device 
The increase in the number of patients awaiting LT and the inability of support systems to 
restore liver function have led to the advent of extracorporeal bioartificial liver (BAL) devices [2]. 
BAL devices are support systems for liver function, which perform detoxification and synthesis, for 
instance, and are connected to the patient′s venous circulation with the possibility of plasma 
separation (Figure 3). The latter flows through the bioreactor where liver cells have been seeded for 
metabolic exchange, and plasma is subsequently returned to the patient [84]. Based on their 
configuration, BAL devices are classified into systems based on hollow fibers, multi-layer 
membranes or a sponge/scaffold base, and floating/encapsulated. Hollow fiber devices are the most 
used in clinical studies. The ideal cellular source has not yet been identified. Primary human 
hepatocytes are useful for these systems but cannot be seeded in BAL devices for clinical studies due 
to their low availability and quality [85]. Only cells similar to highly functional hepatocytes derived 
from pluripotent stem cells showed potential [86]. These cells expressed hepatocyte markers, and 
demonstrated hepatic functions. IPSCs, which cannot yet be used in other applications due to their 
tumorigenic potential, are very useful in BAL systems as these cells would be isolated from the 
patient′s blood by multiple layers of filtering membranes. Thus, while iPSC-derived liver cells may 
not be ideal for cell transplantation, these cells are valid candidates for the BAL system [87]. 
One of the most studied BAL devices is the extracorporeal liver assist device (ELAD), which 
uses the human hepatoblastoma cell line HepG2 C3A in hollow fiber-based dialysis cartridges [87]. 
In this system, the cells grow inside the extracapillary space of a cartridge while the patient′s plasma 
flows inside the lumen of the hollow fibers. The latter, made with a semi-permeable membrane, 
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allow the passage of the patient′s ultrafiltrate to C3A cells while allowing the exchange of toxins and 
nutrients [2]. Another BAL support system, HepatAssist, employs pig hepatocytes within an 
extracapillary compartment of a hollow fiber bioreactor [2]. Despite the wide availability of porcine 
hepatocytes, these cells raise some concerns in terms of xenotransplantation in humans, due to the 
possibility of xenozoonosis [88]. A solution is presented by the work of Sauer et al. that developed 
the extracorporeal hepatic modular support device (MELS) using primary human hepatocytes in a 
3D framework of hollow fiber membranes [89]. 
The effectiveness of BAL systems has been investigated by numerous clinical trials [87]. The 
safety and efficacy of HepatAssist has been attested in the first prospective, randomized, controlled 
trial of an extracorporeal liver support system on patients with fulminant/subfulminant hepatic 
failure. Survival was significantly higher in the BAL group compared to the control group (73% 
versus 59%) [90]. ELAD was tested in a phase III trial, which recruited 203 patients with alcoholic 
hepatitis, of whom 96 were treated with ELAD and 107 with SMT. Comparison of the basic 
characteristics between the two groups did not reveal any significant difference. However, a 
regression analysis highlighted high levels of creatinine, but not of bilirubin. ELAD could potentially 
benefit young subjects with sufficient renal function and less severe coagulopathy [91]. In a trial 
involving 8 patients (2 with ALF, 4 with acute-on-chronic liver failure, and 2 with primary 
non-function), MELS used as bridge therapy showed technical viability and safety of the system [89]. 
Several hurdles with BAL systems need to be surpassed before their effective clinical 
application, such as the difficulty in reaching the minimum number (45 billion) of hepatic cells 
required for a clinical-scale BAL, and the high economic cost deriving from the use of large 
quantities of materials and instruments necessary for cell culture and differentiation, all 
exponentially increasing depending on treatment length [87]. 
 
Figure 3. A Bioartificial Liver (BAL) system: Patient blood is taken from the venous circulation and 
separated from plasma, which flows into a reservoir through a pump system. The plasma then goes 
into a bioreactor inoculated with living cells and returns to the patient after filtration and rejoins the 
blood. 
2.3.3. Bioscaffolds 
Through tissue engineering approaches, a number of artificial organs capable of replacing the 
damaged ones, including heart, bladder, intestines, kidney and liver, have been devised. However, it 
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is not yet possible to recapitulate all the biochemical and architectural complexity of the natural 
microenvironment to ensure long-term survival and functionality of seeded cells. Decellularized 
organs may offer a solution [92,93]. Importantly, the protein composition, topography and 
mechanical properties of the ECM, as well as the microvascular networks for oxygen and nutrient 
transport, as well as metabolite excretion, in these structures are maintained [92,94]. 
Although the use of xenogenic livers is promising, the ideal bioscaffold would be decellularised 
human liver in order to minimize the problems of biocompatibility, immunogenicity and 
hemodynamics due to the different 3D architecture compared to an animal liver. The first successful 
decellularization of a human liver and repopulation with derived human liver cells was performed 
in 2015 by using a novel retrograde, two-step, perfusion flow-rate methodology able to preserve the 
3D hepatic architecture and composition, and guarantee excellent viability, motility and cell 
proliferation [95]. Thereafter, significant progress in the field ensued. It was shown that, under 
controlled conditions, vascular and biliary networks can also be preserved [96]. Both parenchymal 
and non-parenchymal cells can be used to repopulate the human liver scaffolds [97]. Moreover, by 
including human umbilical endothelial cells or HUVEC, these structures can be efficiently 
revascularised [96,97]. With this breakthrough, some problems related to xenogenic sources of liver 
for grafts in patients, such as organ size and revascularisation, have been addressed. 
Implantable engineered cell-based devices aim at improving metabolic function by providing a 
small tissue mass (less than 5%), while to restore the liver′s life-saving functions and promote patient 
survival in case of severe liver diseases, a larger hepatic mass (more than 25%) is required [83]. This, 
in fact, is one of the major challenges faced to date and has become the main objective of the entire 
organ decellularisation and recellularisation technology [83]. Even if the full potential of the 
recellularised human bioscaffolds need to be exploited, one possible use in the clinical setting may 
be to promote diseased cell replacement following partial hepatectomy (the partial liver scaffolds 
were sutured onto the surfaces of partially hepatectomised livers) as described in porcine livers [98]. 
However, there are problems associated with the precise control over the spatial distribution 
and architectural accuracy of the cells infused in the bioscaffolds. This has been tackled by the 
introduction of 3D technology bioprinting. This technology allows the development of accurate, 
detailed and customized engineered structures that mimic tissue and organ functions in vivo and 
involves indirect and direct manufacturing. The indirect bioprinting initially creates negative 
sacrificial molds, followed by casting with the desired positive biomaterial and then selective 
removal of the molds [99]. Instead, the direct ones create 3D structures in a point-by-point and/or 
layer-by-layer manner, to insert more cell types and/or biomaterials in order to create a structure 
with reproducibility and heterogeneity as in vivo. The biomaterial used as ink for 3D printing must 
be biocompatible (to avoid rejection), and with certain viscosity (to determine the correct balance 
between flexibility and maintenance of structural integrity during and after deposition) [100,101]. 
The biomaterial based on Pluronic, which is able to pass from the liquid state in solution to the 
recovery of its shear-thinning hydrogel state at room temperature and upon bioprinting, thus 
avoiding structural collapse, is an example [102]. The stability of the construct is also determined by 
the type of crosslinking that can be physical or chemical. The latter proved to be more stable and not 
subject to dissolution [103]. Liver-like microstructures have been produced with various 
combinations of hydrogels for hepatocyte production [104]. Interestingly, 3D vascularized liver 
constructs made of native liver tissue and tight intercellular junctions, with human primary 
hepatocytes, endothelial cells, and hepatic stellate cells, have proved to be viable and potentially 
useful for drug screening [105]. The use of these hybrid scaffolds as alternatives to LT needs to be 
further investigated in clinical studies. 
2.3.4. Liver Organoids 
Organoids are 3D structures of human tissue that are obtained from primary or stem cells, and 
are capable of reproducing the architectural and functional properties of diverse cell types present in 
a full-sized organ (reviewed in [106]). IPSCs, embryonic or adult healthy or diseased tissue-derived 
stem cells have been employed for organoid formation. Organoids have been used to further hepatic 
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differentiation of stem cells in vitro. For instance, compared to other culture settings, hiPSCs 
co-cultured with supporting non-parenchymal cells, such as human endothelial cells in 3D 
spheroids, showed enhanced differentiation and hepatic function in vitro and in vivo [107]. 
Recently, an unprecedented reproduction of the complex human hepatobiliary pancreatic 
system was achieved [108]. IPSCs derived from healthy donors successfully generated, over time, 
interconnected biliary duct and pancreas domains capable of processing bile acids as well as 
carrying out the pancreatic secretory function (amylase production) in vitro [108]. Hitherto, 
organoids have provided an excellent tool to study biological processes associated with liver 
development and regeneration, disease modelling and determination of drug response to offer 
personalised therapy [109]. By co-differentiating epithelial and stromal lineages derived from 
human pluripotent stem cells into liver organoids, Ouchi et al. succeeded in modelling the stepwise 
process leading to steatohepatitis in vitro [110]. Importantly, using atomic force microscopy, changes 
in stiffness in the fibrotic liver organoids could be monitored efficiently in vitro [110]. Steatohepatitis 
progressively increases in severity (stepping from liver inflammation and fibrosis to end-stage liver 
disease) if no therapy is provided. Thus, it is important to identify the right treatment option very 
early in steatohepatitis-affected patients. Thus, recapitulating precisely a disease in organoids is a 
significant step forward towards finding patient-specific treatment strategies. Hopefully, in the 
future, a way of adopting liver organoids in human liver transplant will be found. 
3. Cell-Free Approach: Extracellular Vesicles 
Apart from physically substituting damaged cells in the liver, transplanted cells have paracrine 
effects (through the secretome) on the microenvironment, thus contributing to the organ 
regeneration processes (Figure 2). Extracellular vesicles (EVs) are part of the cell′s secretome and are 
membrane-defined nanoparticles that participate in intercellular and inter-organ communication 
through exchange of biomolecules (lipids, proteins, and nucleic acid species). Recent advances in the 
characterisation of EV composition and content have highlighted the importance of EVs for 
biomarker discovery for different liver pathologies [111]. 
EVs also represent a cell-free alternative for the therapy of liver diseases, and may be used as a 
bridging therapy to LT in some cases (Figure 4). EVs derived from various sources are being 
assessed for their curative properties in preclinical models of liver diseases. Most studies have 
hitherto focused on the healing properties of non-coding RNAs (micro-RNAs or miRNAs) present in 
the EVs [112,113]. Adipose-tissue derived EVs, genetically modified to express miR181-5p for 
instance, were shown to have anti-fibrotic effects on the liver through autophagy activation and 
modulation of fibrogenesis-related pathways [114]. In a model of non-alcoholic steatohepatitis, 
treatment with EVs derived from LSCs (human liver stem cells) significantly alleviated liver 
inflammation and fibrosis by reprogramming hepatic gene expression through the protein cargo 
(mainly cytokines and growth factors) contained in the EVs [115]. EVs isolated from iPSCs were also 
shown to have beneficial effects on the liver by inducing a decrease in expression of profibrogenic 
markers (α–smooth muscle actin, collagen1α1, fibronectin, and tissue inhibitor of 
metalloproteinases–1) and responses (chemotaxis and proliferation) in human hepatic stellate cells 
in vitro, and to reduce liver fibrosis and improve liver function in murine models of liver injury and 
fibrosis [116]. These effects could be mediated by shuttling of miRNAs harboured by the 
iPSC-derived EVs (such as miR-92a-3p, miR-26a-5p) into hepatic stellate cells [116]. Long 
non-coding RNAs present in EVs may also provide beneficial effects. For instance, in the model of 
fulminant hepatic failure, bone marrow MSC-derived EVs, highly enriched in the long non-coding 
RNA, Y-RNA-1, dramatically improved survival of mice versus placebo-administered controls by 
reducing hepatocyte apoptosis [117]. More studies are needed to analyse what happens upon EV 
treatment in the case of more advanced liver fibrosis or cirrhosis. Moreover, the dosage and 
frequency of EV administration may be dependent on liver disease type. In preclinical models, such 
as those of non-alcoholic steatohepatitis and CCL4-induced liver injury, administration of EVs 2 to 3 
times per week showed a reduction in profibrotic events in the liver [115,116]. On the other hand, in 
the bile duct ligation model, daily injection of EVs was required to observe an anti-fibrotic effect 
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[116]. It is also important to assess, in the long-term, the effect of EV (or cell) injection in models with 
portal hypertension, which develops as a consequence of liver fibrosis, as intravenous delivery may 
lead to ascites formation (personal observation). All these issues have to be addressed before 
undertaking human studies. To our knowledge, to date no clinical trials have been undertaken to 
investigate their therapeutic potential in human liver diseases. This is probably related to the fact 
that obtaining cost-effective, clinical grade stem cell-derived EVs in sufficient quantity to achieve 
therapeutic effects in patients has not been attained yet. 
 
Figure 4. Action of EVs on liver repair. Upon injury, hepatocytes release EVs containing restorative 
non-coding RNAs, proteins and lipids that induce the regenerative process in the liver by enhancing 
survival and proliferation of resident cells, neovascularisation, and by modulating niche 
homeostasis. Stem cell therapy potentiates this process by providing EVs with anti-inflammatory 
and immunomodulatory properties to the damaged liver. These EVs may have anti-fibrotic effects 
and prevent cytotoxicity in the liver, hence contributing to slowing the progression to end-stage liver 
diseases. 
4. Cell-Based and Cell-Free Gene Therapy for Liver Diseases 
With respect to viral vectors that present some limitations for clinical applications, cells offer an 
alternative platform for gene correction prior to transplantation in the liver [118]. Advantages lie in 
the fact that gene correction can be efficiently controlled and monitored in vitro, and possible 
tumorigenic changes assessed, prior to transplantation in patients. Several strategies have been 
employed to correct genetic defects in stem cells or to reboot genes that modulate liver function. 
Patient-derived iPSC modelling of liver diseases ex vivo has been used to test the efficiency of 
exogenous gene delivery or correction. Genome editing strategies, such as TALEN or CRISPR/Cas9 
systems have been employed for this purpose [65]. 
Importantly, as non-viral agents, EVs derived from wild-type human LSCs were also capable of 
restoring enzymatic deficiency in human LSCs isolated from the liver of a patient with type I 
citrullinemia, suggesting that these nanometer-sized vesicles can transfer argininosuccinate 
synthase (ASS1 enzyme) and its mRNA, hence achieving gene therapy for certain inherited 
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disorders [119]. EVs also transfer non-coding RNAs, such as microRNAs (miRNAs) capable of 
modulating gene expression in the target cells. For instance, MSC-EV-associated miR-122 was 
successfully transferred to hepatic stellate cells in vitro and inhibited the expression of key genes 
involved in the synthesis of collagen in these cells [120]. Once identified, the therapeutic miRNAs 
can be enriched in the EVs, by electroporation into EV or by modulating the expression in the cells 
of origin, to achieve better efficiency in patients with severe liver diseases [120,121]. It is important 
to determine which bioactive molecules are harboured by EVs from different cell sources in order to 
apply patient-tailored therapy in the case of genetic deficiencies. The potential of the cell-free EVs in 
this direction needs to be fully exploited. 
5. Conclusions 
In an era of organ-shortage crisis, cell-based strategies have made significant leaps forward 
while keeping pace with the evolving biotechnological advances. However, long-term studies 
assessing liver histological status post-cell therapy to exclude inflammation and fibrosis as well as 
biliary problems, in order to ascertain the safety in patients with severe liver diseases, are lacking. 
The heterogeneity of factors that cause liver failure as well as the patients′ comorbidities can also 
nuance the benefits of cell-based and cell-free interventions. Moreover, in the case of liver failure, a 
fully functional, ready-to-use, liver graft is required. All these issues still need to be addressed, and 
current literature review reveals that, through multidisciplinary efforts, including those of cell and 
developmental biologists, bio-engineering scientists, immunologists and transplantation surgeons, 
we are on track for achieving this. 
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